Scala Biodesign, a Tel Aviv-based developer of a cloud-based no-code protein design platform, has raised $16M in Series A funding led by Grove Ventures. ScalaOS fuses evolution, physics, and AI to enable one-shot designs of superior proteins like enzymes, antibodies, and therapeutics. The capital will accelerate platform development and team expansion.
AI Biotech Funding Accelerates
The raise aligns with a March 2026 surge in AI biotech investments, including Congruence Therapeutics' $39.5M round on March 23 per VentureRadar. Cradle holds $102M total funding for its generative AI protein platform. Meanwhile, Generate:Biomedicines completed a $400M IPO in February 2026 according to BioPharma Trend. Scala's no-code approach differentiates by delivering multi-parameter optimizations in a single cycle.
Protein Instability Halts Drug Pipelines
Protein engineering remains a core bottleneck in biotech, with instability often emerging late in clinical trials per Axios Pro. Traditional methods require years of iterative lab experiments, costing millions and delaying therapies. Scala's platform addresses this by optimizing stability, activity, and expression simultaneously without trade-offs.
One-Shot Designs Fuse AI and Physics
ScalaOS integrates physics-based modeling, evolutionary data, and LLMs to introduce dozens of mutations in one design round, validated by over 130 peer-reviewed publications from company site. Success stories include a 7x enzyme conversion boost and a malaria vaccine candidate now in Phase II trials. Unlike Arzeda's $130M+-funded de novo focus requiring iterations, Scala excels in broad optimization for existing proteins.
Cradle's $100M+ platform guides biologists iteratively, while ScalaOS offers no-code, single-shot results embeddable in R&D workflows. Recent partnerships, like with Ribbon Bio and Nuclera, achieved 9x purification yield improvements via company posts.
Grove Ventures Backs Weizmann Spinout
Grove Ventures led the round, joined by TLV Partners, Deep Insight, and a NIS 15M (~$4.8M) Israel Innovation Authority grant, bringing total funding to $21.5M per Ctech. This mix signals strategic conviction in Israel's biotech export potential. Investor Renana Ashkenazi highlighted the opportunity:
"Improving the speed and reliability of protein design remains one of the most impactful opportunities in biotechnology."
The funding validates adoption by 9 of the top 20 pharma companies, including Boehringer Ingelheim, within eight months of launch.
AI Protein Market Projects $7B Growth
The AI protein design market stands at $719M in 2026, projected to reach $6.98B by 2033 at 18.59% CAGR according to 360iResearch. Broader protein engineering hits $5.95B with 16.6% CAGR per Precedence Research. Post-AlphaFold advances fuel demand for tools like ScalaOS amid U.S. DOE's $293M AI-biotech funding call via Ethanol Producer.
Antiverse' $20M+ focuses narrowly on antibodies, contrasting Scala's versatility across enzymes and therapeutics.
Weizmann Founders Drive Credibility
Co-founders CEO Ravit Netzer and CTO Adi Goldenzweig earned PhDs in computational protein design at Weizmann Institute under Prof. Sarel Fleishman, now Chief Scientist per LinkedIn profiles. Their lab pioneered one-shot methods licensed to Scala, underpinning 130+ publications and real-world wins like stabilizing Boehringer targets. This academic pedigree, plus recent exec hires from Intel and Merck, bolsters scaling.
Platform Expansion Targets Global Scale
Post-raise, Scala plans aggressive hiring in R&D, sales, and software engineering from LinkedIn activity. With events at SynBioBeta and PEGS Boston, and partnerships expanding, the 25-person team eyes broader biomanufacturing and green chemistry adoption.